HR 8013 · 116th Congress · Health
End Taxpayer Funding of Gender Experimentation Act of 2020
Bill Progress
✓
Introduced2
Committee3
House Vote4
Senate5
EnactedLatest: Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.(2020-08-11)
Plain Language Summary
[AI summary unavailable — showing source text]
End Taxpayer Funding of Gender Experimentation Act of 2020 This bill modifies provisions relating to federal funding for, and health insurance coverage of, gender reassignment medical interventions, which include surgical remedies and hormone therapy arising from a conflict between an individual's gender identity and the sex the individual has or was identified as having at birth. Specifically, the bill prohibits the use of federal funds for gender reassignment medical interventions or for health coverage that includes such interventions. Additionally, such interventions may not be provided in a federal health care facility or by a federal employee. Under current law, coverage of these interventions through Medicare and Medicaid is generally determined at the state level. The bill's restrictions regarding the use of federal funds do not apply to treatment of individuals with medically verifiable disorders of sex development, such as individuals born with atypical development of chromosomal, gonadal, or anatomical sex. The bill also prohibits qualified health plans from including coverage for gender reassignment medical interventions. Further, plans that include coverage for such in…
Summarized by Claude AI · Non-partisan · For informational purposes only
Cosponsors (12)
12 Republicans